Article
Hematology
Jasmine M. Zain, Paul Hanona
Summary: Aggressive T-cell lymphomas present challenges in prognosis, but molecular pathogenesis studies have revealed unique features of different subtypes, leading to more targeted treatment options. Various targeted therapies, immunotherapies, and genetic mutation analysis play crucial roles in prognosis assessment and treatment selection for patients.
AMERICAN JOURNAL OF HEMATOLOGY
(2021)
Article
Biotechnology & Applied Microbiology
Mark B. Leick, Marcela Maus, Matthew J. Frigault
Summary: Large B cell lymphoma can be cured with standard chemoimmunotherapy in most cases, but patients with refractory or relapsed disease have limited treatment options historically. Two gene-modified CAR-T cell therapies have been approved for these indications. Clinical decisions and management surrounding these gene-modified "living drugs" are nuanced and complex, involving factors such as patient selection, screening procedures, and follow-up.
Review
Oncology
Carlos Murga-Zamalloa, Kedar Inamdar
Summary: Mature T-cell lymphomas are aggressive and challenging to diagnose tumors, and recent molecular and histopathological findings have improved understanding of their classification and diagnosis.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
M. Nieves Calvo-Vidal, Nahuel Zamponi, Jan Krumsiek, Max A. Stockslager, Maria Revuelta, Jude M. Phillip, Rossella Marullo, Ekaterina Tikhonova, Nikita Kotlov, Jayeshkumar Patel, Shao Ning Yang, Lucy Yang, Tony Taldone, Catherine Thieblemont, John P. Leonard, Peter Martin, Giorgio Inghirami, Gabriela Chiosis, Scott R. Manalis, Leandro Cerchietti
Summary: Oncogenic HSP90 plays a crucial role in coordinating metabolic pathways in cancer cells, supporting energy production and cellular maintenance. Inhibition of oncogenic HSP90 may disrupt metabolic reprogramming driven by MYC, suggesting a potential novel therapeutic strategy for lymphoma cells.
Review
Biochemistry & Molecular Biology
Natsumi Hara, Yu Sawada
Summary: Epigenetic modifications rarely occur alone, but rather form a network to control the epigenetic system. Limited knowledge exists about the epigenetic changes associated with cutaneous lymphomas. This review focuses on cutaneous T-cell lymphomas, summarizing the chemical modifications of DNA methylation, histone acetylation, and methylation. Current research on epigenetic-targeted therapy against cutaneous T-cell lymphomas is discussed.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Dermatology
Josephine Franceschi, Marine Ehret, Laetitia Visseaux, Anne Durlach, Coralie Barbe, Eric Durot, Florent Grange
Summary: Aggressive primary cutaneous T-cell lymphomas consist of various subtypes with different prognoses. Advanced-stage mycosis fungoides has a relatively better prognosis, while Sezary syndrome and other subtypes have a poorer prognosis.
ACTA DERMATO-VENEREOLOGICA
(2022)
Review
Oncology
Chun-fung Sin, Pui-hei Marcus Man
Summary: ETP-ALL, a distinct subtype of T-ALL, has poor prognosis and limited novel therapy options. Diagnosing and managing ETP-ALL remains challenging, despite advances in understanding its molecular mechanisms. Risk-adapted therapy and allogenic stem cell transplant play an emerging role in improving patient outcomes, with potential novel therapies proposed based on current knowledge.
FRONTIERS IN ONCOLOGY
(2021)
Review
Pharmacology & Pharmacy
Sushant Kumar, Bhavuk Dhamija, Diksha Attrish, Vinanti Sawant, Manju Sengar, Jayashree Thorat, Tanuja Shet, Hasmukh Jain, Rahul Purwar
Summary: T cell lymphomas are a diverse group of Non-Hodgkin lymphomas with a wide range of clinical manifestations, driven by genetic alterations and cellular processes such as T cell signaling and differentiation. Targeting genetic abnormalities and oxidative stress may lead to improved therapeutic outcomes and new combination treatments for T cell lymphomas.
PHARMACOLOGY & THERAPEUTICS
(2022)
Article
Oncology
Stephen J. Schuster, Constantine S. Tam, Peter Borchmann, Nina Worel, Joseph P. McGuirk, Harald Holte, Edmund K. Waller, Samantha Jaglowski, Michael R. Bishop, Lloyd E. Damon, Stephen Ronan Foley, Jason R. Westin, Isabelle Fleury, P. Joy Ho, Stephan Mielke, Takanori Teshima, Murali Janakiram, Jing-Mei Hsu, Koji Izutsu, Marie Jose Kersten, Monalisa Ghosh, Nina Wagner-Johnston, Koji Kato, Paolo Corradini, Marcela Martinez-Prieto, Xia Han, Ranjan Tiwari, Gilles Salles, Richard T. Maziarz
Summary: The JULIET trial evaluated the long-term treatment outcomes and safety of tisagenlecleucel in adult patients, showing durable activity and manageable safety profiles in patients with relapsed or refractory aggressive B-cell lymphomas. Tisagenlecleucel compared favorably with conventional therapeutic approaches for patients with large B-cell lymphomas that are refractory to chemoimmunotherapy or relapsing after second-line therapies.
Article
Hematology
Alexandra C. Hristov, Trilokraj Tejasvi, Ryan A. Wilcox
Summary: Cutaneous T-cell lymphomas involve a group of T-cell neoplasms affecting the skin, typically classified as Mycosis Fungoides or Sezary Syndrome. Diagnosis requires integration of clinical and histopathologic data; treatment is risk-adapted based on TNMB staging, with options including skin-directed therapies or systemic treatments.
AMERICAN JOURNAL OF HEMATOLOGY
(2021)
Letter
Oncology
Qiusha Huang, Xiao-hui Zhang, Delong Liu
Summary: Due to concerns about fratricide, the development of CAR T cells for T cell malignancies lags behind that for B cell malignancies. Efforts are underway to modify T cell biomarkers so that re-engineered CAR T cells can target T cell malignancies. CD3 and CD7, two pan-T cell surface biomarkers, have been knocked out or downregulated using genome editing technology or protein blockers to enable re-engineered T cells to target T cells without causing fratricide. We have summarized several recent reports on CAR T cells for the therapy of T cell leukemia/lymphoma from the 2022 ASH Annual Meeting, including updates on clinical trials of TvT CAR7, RD-13-01, and CD7 CART.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2023)
Article
Biophysics
Alberto Mussetti, Leyre Bento, Mariana Bastos-Oreiro, B. Rius Sansalvador, Carmen Albo, Rebeca Bailen, Pere Barba, Ana Benzaquen, Javier Briones, Ana Carolina Caballero, Antonio Campos, Ignacio Espanol, Christelle Ferra, Sebastian Garzon Lopez, Pedro Antonio Gonzalez Sierra, Luisa Maria Guerra, Rafael Hernani, Gloria Iacoboni, Ana Isabel Jiminez Ubieto, Mi Kwon, Lucia Lopez Corral, Oriana Lopez-Godino, Maria Carmen Martinez Munoz, Nuria Martinez-Cibrian, Juan Montoro Gomez, Laura Perez-Ortega, Guillermo Orti, Valentin Ortiz-Maldonado, Maria-Jesus Pascual, Maria Perera, Antonio Perez, Juan Luis Reguera, Jose M. Sanchez, Jaime Sanz, Anna Torrent, Lucrecia Yanez, Rosario Varela, Izaksun Ceberio Echechipia, Dolores Caballero, Anna Sureda
Summary: Anti-CD19 CART has been adopted as the standard third-line therapy for treating ABCL after failure of second-line therapy. This study compared the efficacy of CART with alloHCT and found that CART had similar progression-free survival to alloHCT, especially in patients with chemosensitive diseases. However, CART had lower non-relapse mortality.
BONE MARROW TRANSPLANTATION
(2023)
Article
Hematology
Alexandra C. Hristov, Trilokraj Tejasvi, Ryan A. Wilcox
Summary: Cutaneous T-cell lymphomas are a diverse group of T-cell neoplasms involving the skin. The diagnosis requires the integration of clinical and histopathologic data. Risk-adapted therapy involves observation or skin-directed therapies for patients with limited skin involvement, and systemic therapies for patients with advanced-stage disease, with the possibility of stem-cell transplantation for selected patients.
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Article
Hematology
Alexandra C. C. Hristov, Trilokraj Tejasvi, Ryan A. A. Wilcox
Summary: Approximately one-fourth of primary cutaneous lymphomas are B-cell derived and are classified into three subgroups: PCFCL, PCMZL, and PCDLBCL, LT. Diagnosis is based on histopathologic review and immunohistochemical staining of a skin biopsy. Risk-stratification is important, with PCFCL and PCMZL having a good prognosis and PCDLBCL, LT having a poor prognosis. Treatment options vary based on the subtype, with local radiation therapy for PCFCL and PCMZL, and systemic treatment for PCDLBCL, LT.
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Review
Cell Biology
Periklis G. Foukas, Bettina Bisig, Laurence de Leval
Summary: Gastrointestinal (GI) tract is involved in approximately one-third of extranodal non-Hodgkin lymphomas, with most cases diagnosed in the stomach, duodenum, or proximal small intestine. Diffuse large B-cell lymphoma and extranodal marginal zone lymphoma are the most common types. While morphology and immunophenotype play a role in diagnosis, it is increasingly important to incorporate molecular genetic markers.
Article
Hematology
Jasmine M. Zain, Paul Hanona
Summary: Aggressive T-cell lymphomas present challenges in prognosis, but molecular pathogenesis studies have revealed unique features of different subtypes, leading to more targeted treatment options. Various targeted therapies, immunotherapies, and genetic mutation analysis play crucial roles in prognosis assessment and treatment selection for patients.
AMERICAN JOURNAL OF HEMATOLOGY
(2021)
Article
Hematology
Swetha Kambhampati, Monica Saumoy, Yecheskel Schneider, Stacy Pak, Lihua Elizabeth Budde, Matthew G. Mei, Tanya Siddiqi, Leslie L. Popplewell, Yi-Ping Wen, Jasmine Zain, Stephen J. Forman, Larry W. Kwak, Steven T. Rosen, Alexey V. Danilov, Alex F. Herrera, Nikhil R. Thiruvengadam
Summary: In patients with treatment-naive diffuse large B-cell lymphoma (DLBCL), the POLARIX study reported that pola-R-CHP showed improvement in 2-year progression-free survival compared to R-CHOP. However, the overall survival and safety were similar. Cost-effectiveness analysis showed that pola-R-CHP was cost-effective within a certain willingness-to-pay threshold but not in all scenarios.
Article
Oncology
Julio C. Chavez, Francine M. Foss, Basem M. William, Jonathan E. Brammer, Sonali M. Smith, Anca Prica, Jasmine M. Zain, Joseph M. Tuscano, Harsh Shah, Neha Mehta-Shah, Praveen Ramakrishnan Geethakumari, Ben X. Wang, Stephanie Zantinge, Lisa Wang, Ling Zhang, Anmarie Boutrin, Weiguang Zhao, Lily Cheng, Nathan Standifer, Lisa Hewitt, Enowmpey Enowtambong, Weiping Shao, Shringi Sharma, Gianluca Carlesso, Jeffrey A. Moscow, Lillian L. Siu
Summary: This study aims to investigate the safety and clinical activity of the anti-ICOS monoclonal antibody MEDI-570 in patients with T-NHL. The results showed that MEDI-570 had good tolerability in relapsed/refractory AITL patients and had sustained inhibitory effects on ICOS thorn T lymphocytes.
CLINICAL CANCER RESEARCH
(2023)
Article
Dermatology
Zhen Han, Xiwei Wu, Hanjun Qin, Yate-Ching Yuan, Jasmine Zain, D. Lynne Smith, Oleg E. Akilov, Steven T. Rosen, Mingye Feng, Christiane Querfeld
Summary: This study investigated the effects of CD47 and PD-L1 immune checkpoint blockades on cutaneous T-cell lymphoma (CTCL). The results showed that dual targeting of CD47 and PD-L1 enhanced immune activity and suppressed tumor growth.
JOURNAL OF INVESTIGATIVE DERMATOLOGY
(2023)
Article
Medicine, General & Internal
George Semeniuk, Bahareh Bahadini, Eugene Ahn, Jasmine Zain, Jessica Cheng, Ameish Govindarajan, Judy Rose, Richard T. Lee
Summary: Integrative oncology is an emerging field that combines conventional cancer treatments with integrative therapies to improve quality of life for cancer patients. Clinical research has shown the benefits of these approaches in symptom management and quality of life, leading to their inclusion in national guidelines.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Hematology
Jia Ruan, Jasmine Zain, Brett Palmer, Borko Jovanovic, Xinlei Mi, Alok Swaroop, Jane N. Winter, Leo I. Gordon, Reem Karmali, Jonathan Moreira, Adam M. Petrich, Barbara Pro
Summary: This study evaluated the combination of romidepsin and lenalidomide as initial treatment for PTCL and found that it is feasible and effective, showing promising overall response rates and survival outcomes.
Article
Hematology
Shin Yeu Ong, Stacy Pak, Matthew Mei, Yan Wang, Leslie Popplewell, John H. Baird, Alex F. Herrera, Geoffrey Shouse, Liana Nikolaenko, Jasmine Zain, James Godfrey, Myo Htut, Ahmed Aribi, Ricardo Spielberger, Joshua Mansour, Stephen J. Forman, Joycelynne Palmer, Lihua E. Budde
Summary: The study retrospectively evaluated the outcomes of using bendamustine as an alternative lymphodepletion therapy for aggressive B-cell lymphoma before axicabtagene ciloleucel (axi-cel). The results showed comparable efficacy and lower neurotoxicity compared to the standard fludarabine/cyclophosphamide (Flu/Cy) regimen.
AMERICAN JOURNAL OF HEMATOLOGY
(2023)